Predictive models may help in determining the risk/benefit ratio of allogeneic hematopoietic stem cell transplantation (HSCT) in acute leukemia (AL). Using a machine-learning algorithm we have previously developed the AL-European Society for Blood and Marrow Transplantation (EBMT) score for prediction of mortality following transplantation. We report here the first external validation of the AL-EBMT score in a cohort of AL patients from the Italian national transplantation network. A total of 1848 patients transplanted between the years 2000-2014 were analyzed. The median age was 45.9. Indications for HSCT were Acute Myeloid Leukemia (68.1%) and Acute Lymphoblastic Leukemia (31.9%). The majority of patients were in first complete remission (60.4%), and received myeloablative conditioning (81.3%). Median follow-up was 2 years. The score was well-calibrated for prediction of day 100 mortality and 2-year overall survival (OS), leukemia free survival (LFS), and nonrelapse related mortality, with corresponding area under the receiveroperator curves of 0.698, 0.651, 0.653, and 0.651, respectively. Increasing score intervals were associated with a decreasing probability of 2-year OS and LFS. The highest scoring group was associated with a hazard ratio of 3.16, 2.8, and 2.27 for 2-year OS, LFS, and NRM, respectively. In conclusion, the AL-EBMT score identified three distinct risk groups and was predictive of OS. It is a valid tool for stratifying the risk of acute leukemia patients undergoing allogeneic HSCT.
| I N T R O U D C T I O N
Allogeneic hematopoietic stem cell transplantation (HSCT) is an intensive therapy used to treat high-risk malignant hematological disorders and other life-threatening hematological diseases. 1 Nonrelapse mortality (NRM) following transplantation is attributed to graft-versus-host disease, infection, organ toxicity, and other causes. A complex network of parameters related to the patient (eg, age and comorbidities), disease (eg, remission status at transplantation and cytogenetics), donor (eg, human leukocyte antigen [HLA] matching), and procedure (eg, conditioning) all have meaningful effects. [2] [3] [4] Although the risk for NRM differs considerably among individuals, the establishment of a robust prognostic system is still needed to guide patient counseling before transplant.
Several prognostic scoring systems, including the European Society for Blood and Marrow Transplantation (EBMT) risk score and the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI), are utilized in prediction of allogeneic HSCT outcomes. 3, 5 These scores may aid therapeutic decision. However, their predictive capacity varies. 3, [5] [6] [7] Using the Alternating Decision Tree (ADT) machine learning algorithm, 8, 9 we have recently developed and internally validated a prognostic model, the Acute Leukemia (AL)-EBMT score, for prediction of mortality following allogeneic HSCT in a large cohort of AL patients vides an individualized estimated probability of day-100 mortality following transplantation for AL patients; eg, for a patient receiving a score of 6 the probability of death at day 100 is 6%. In addition, the score was categorized into 10 intervals which were shown to be predictive of overall survival (OS), leukemia free survival (LFS) and NRM 2 years after transplantation; eg, patients with scores in the range of 5.55 to 6.51 had a probability of 67.3 (64-70.6, 95% confidence interval [CI]) for 2-year OS. 10 The AL-EBMT score has yet to be validated on an independent data set.
In the present study, we aimed to validate the predictive capacity of the AL-EBMT score on an independent data set of acute leukemia patients from the Italian transplantation network (Gruppo Italiano Tra-
We explored the score's ability to
give a probabilistic estimation of mortality at 100 days post-HSCT. In addition, we divided the original cohort's scores into terciles, which were evaluated for validity in the predicting 2-year OS, LFS and NRM in the GITMO cohort.
| M E T H O D S

| Study design
This was a retrospective validation study of the AL-EBMT score on a cohort of acute leukemia patients. The principles of Transparent
Reporting of a prediction model for Individual Prognosis Or Diagnosis (TRIPOD) were followed. 12, 13 Data from the GITMO registry were analyzed for external validation of the AL-EBMT score. GITMO is the Ital- 
| Outcomes
All outcomes were measured from the time of allogeneic HSCT. NRM was defined as death without previous relapse/progression. LFS was defined as survival without leukemia progression or relapse. Competing risk analysis was used to calculate cumulative incidence of 24-month NRM, using the Gray test to test differences between AL-EBMT score groups. OS and LFS were estimated using the Kaplan-Meier method;
hazard ratios were computed between subgroups using Cox regression for OS and competing risk regression for NRM. Competing risk regression was used to compute NRM cumulative incidence rates, considering relapse/progression as the competing event. Calibration and discrimination, assessed with the time-dependent area under the receiver operating characteristic curve (AUC), 13, 15 were used to evaluate the score's quality. Calibration reflects the agreement between outcome predictions from the model and the observed outcomes.
Discrimination refers to the ability of a prediction model to differentiate between those who do or do not experience the outcome event,
and ranges from 0.5 (ie, prediction is not better than chance) to 1 (ie, the predicted risk for all individuals who develop the outcome is higher than for all individuals who do not experience the outcome). 13, 16 All statistical analysis were performed using SPSS (v.21) and R (v.3.2.4).
| R E S U L T S 3.1 | Patient population
Characteristics of 1848 analyzed patients are listed in Table 1 . Median follow-up (95% CI) was 2 years (1.9-2.1). The majority of patients had AML (68.1%), were in CR1 (52.3%) and received myeloablative conditioning (MAC) (78.0%). Grafts from matched sibling donors were used in 50.4% of patients. Stem cell source was bone marrow in 30.1% of patients. More than half of the patients were transplanted after 2011.
OS at 2 years (95% CI) was 55.2% (52.7-57.9), LFS at 2 years was 48.9% (46.4%-51.6%), and NRM at 2 years was 19.9% (18.0-22.0). The cohort differed (P < .05) from the EBMT data set in all parameters included in the ADT score (Supporting Information Table S1 ). In a subanalysis of patients with available comorbidity data (n 5 893) the HCT-CI score ranged from 0 to 7, with 61.6%, 24.0%, and 14.4% having scores of 0,1-2, and 3, respectively.
| Prediction of day-100 mortality in the GITMO cohort
As in the original publication, 10 we first evaluated the AL-EBMT score as a continuous parameter to predict overall mortality 100 days following allogenic HSCT in the GITMO cohort. The AL-EBMT score shows similar performance to the original EBMT cohort, with an AUC of 0.698 and good calibration (r 5 0.9) (Supporting Information Figure S1 ).
| The AL-EBMT's risk-score groups
The large sample size, including almost 30 000 patients in the original AL-EBMT score development study, 10 allowed for categorization of the AL-EBMT score into 10 intervals and assessment of their impact on 2-year outcomes. Using the same 10 categories in the GITMO cohort (n 5 1848) was not reasonable owing to the smaller sample size.
We therefore went back to original EBMT cohort (n Figure 1 ).
When the 3 categories of the AL-EBMT score were studied in a Cox regression model for 2-year OS and LFS and a competing risk regression model for NRM, the categories stratified patients into distinct risk groups ( including patients the patients with available HCT-CI score (n 5 893), the AL-EBMT remained predictive of the outcomes assessed (Table 3) .
| Performance measures
The categorized AL-EBMT score was well-calibrated for all outcomes assessed (Supporting Information Figure S2 ). The score's discrimination 
| DISCUSSION
Acute leukemia is the leading indication for allogeneic HSCT. Thus, assessing the risk associated with transplantation in this population is of great importance, and can be used for informed decision-making and, potentially, personalization of the transplant procedure. In this retrospective analysis, we have externally validated the AL-EBMT score, a prognostic scoring system for prediction of outcomes following allogeneic HSCT in acute leukemia. An increasing score correlated with increasing probability of mortality at 100 days after HSCT. Furthermore, when categorized into 3 intervals, the score was associated with an increase in hazard of OS, LFS, and NRM at 2 years following HSCT.
The AL-EBMT score was developed on registry data from the Acute Leukemia Working Party of the EBMT. Validating the score on the GITMO registry was appealing as the registry comprises detailed data on transplantations from over 80 centers. Hence, performance of the score on the GITMO cohort is likely to be generalizable. Furthermore, the high data quality provided by GITMO has been the source of several major publications which have had meaningful effect on HSCT practice. 7, [17] [18] [19] [20] Most centers in the GITMO network additionally report transplantation data to the EBMT registry. To assure that the validation cohort was independent, we excluded patients who were previously included in original EBMT cohort. Furthermore, the EBMT cohort Table S1 ). Patients in the current dataset were older (median age of 46 vs 43, P < .001), more likely to receive a graft from an unrelated donor (49.6% vs 46.1%, P 5 .004) and to receive a myeloablative conditioning regimen (81.3% vs 71.5%, P < .001). Despite these differences, the AL-EBMT maintained its performance. Overall, our results indicate the robust nature of the score.
The HCT-CI is a valid tool for risk stratification of HSCT patients.
In our population, the index was only available for 893 (48%). The majority of patients had a score of 0, differing from the HCT-CI distri- The AL-EBMT score was developed using the Alternating Decision Tree machine learning algorithm, which does not depend on prior assumptions regarding distribution of data and readily detects interactions between features. 10, 11, 27 Our findings support the incorporation of machine learning algorithms and the data mining approach as tools for analyzing and modeling clinical data. Second, in order to comply with good practice of prognostic modeling, we adhered to the TRI-POD statement, requiring among other things, reporting on the models' discrimination (AUC) and calibration. 12, 13 When reviewing the vast majority of the HCT-CI and EBMT score validation studies, few meet these standards. 3, [5] [6] [7] [28] [29] [30] [31] To ensure an unbiased appraisal of prediction models quality and utility, the process of model development and validation should be transparent, as proposed by TRIPOD.
The study has several limitations. First, despite being an independent validation set, GITMO centers report to the EBMT, hence, validation in non-European centers is still warranted. Nevertheless, as discussed above, there are several features, including year of transplantation and population characteristics that are unique to the population analyzed (Supporting Information Table S1 ). Second, we were only able to calculate the HCT-CI for 893 patients. Thus, the sample size did not allow for development of an integrated AL-EBMT HCT-CI prognostic system, which may further improve discrimination. Finally, this was a retrospective registry analysis, subject to the typical biases and confounders of such studies such as selection and measurement biases.
Therefore, prospective validation is warranted.
| C O NC LU S I O N S
In conclusion, in this retrospective analysis we have externally validated the prognostic utility of the AL-EBMT score in a cohort of acute leukemia patients. The continuous score can be used to estimate the individual probability for overall mortality at day 100 following HSCT.
Furthermore, when categorized into 3 intervals, the score was discriminatory for OS, LFS, and NRM at 2 years. Overall, the score's potential applications include pre-transplantation risk assessment and stratification, patient counseling during informed consent sessions, and tailoring transplantation regimens or referring to alternative treatments according to transplantation risk. Future elaborations of this model should include other types of input such as genetic data, which could further improve the performance of the AL-EBMT score. 32 Moreover, our analysis suggests that integrating data on comorbidities with the AL-EBMT score could further promote the risk stratification.
ACKNOWLEDGMENTS
This study was supported by The Varda and Boaz Dotan Research
Center in Hemato-Oncology affiliated with the CBRC of Tel Aviv
University.
